The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...

APAC offers stability in an increasing challenging global geopolitical environment for clinical stage drug development.

Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...

AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing ...

Trump's pick for HHS secretary who endured confirmation hearings last week—has repeatedly criticized industry ties to the FDA ...

Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio— have products in the pipeline that could ...

The layoffs will allow Ironwood to dedicate more resources to pushing its lead molecule apraglutide through a Phase III trial ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...